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ABSTRACT
Sequence-specific targeting of genomic DNA by
triplex-forming oligonucleotides (TFOs) is a promis-
ing strategy to modulate in vivo gene expression.
Triplex formation involving G-rich oligonucleotides
as third strand is, however, strongly inhibited
by potassium-induced TFO self-association into
G-quartet structures. We report here that G-rich
TFOs with bulge insertions of (R)-1-O-[4-(1-pyr-
enylethynyl)-phenylmethyl] glycerol (called twisted
intercalating nucleic acids, TINA) show a much lower
tendency to aggregate in potassium than wild-type
analogues do. We designed purine-motif TINA–TFOs
for binding to a regulatory polypurine-polypyrimidine
(pur/pyr) motif present in the promoter of the KRAS
proto-oncogene. The binding of TINA–TFOs to the
KRAS target has been analysed by electrophoresis
mobility shift assays and DNase I footprinting experi-
ments. We discovered that in the presence of pota-
ssium the wild-type TFOs did not bind to the KRAS
target, differently from the TINA analogues, whose
binding was observed up to 140mM KCl. The
designed TINA–TFOs were found to abrogate the
formation of a DNA–protein complex at the pur/pyr
site and to down-regulate the transcription of CAT
driven by the murine KRAS promoter. Molecular
modelling of the DNA/TINA–TFO triplexes are also
reported. This study provides a new and promising
approach to create TFOs to target in vivo the
genome.
INTRODUCTION
Polypurine-polypyrimidine (pur/pyr) motifs are potential
sites of triplex formation that have been identiﬁed through
the genome with a relatively high frequency in the control
region of the genes (1). As pur/pyr sequences are often
located immediately upstream of transcription initiation
sites, triplex forming oligonucleotides (TFOs) are attrac-
tive molecules to speciﬁcally modulate gene expression
(2–5). TFOs are designed to bind to the major groove of
the pur/pyr sequence through the formation of a triple-
helical complex stabilized by hydrogen bonds in the
Hoogsteen or reverse-Hoogsteen conﬁguration, depending
on the nature of the third strand. When TFOs contain C
and T nucleotides, they bind to the target in the parallel
orientation through the formation of Hoogsteen hydrogen
bonds (CT triplex motif) (6–8). In contrast, TFOs
containing G and A/T nucleotides bind to the target in
an antiparallel orientation, with reverse-Hoogsteen hydro-
gen bonds, although GT-TFOs may in some cases prefer a
parallel binding (9). Since in the parallel triplex motif the
cytosines of the third strand are protonated, CT-TFOs
show poor binding at neutral pH and are therefore not
very useful to manipulate gene expression in culture cells
or in vivo. For these applications AG-and GT-TFOs are
preferred because they have no pH-limits. However, the
binding of G-rich TFOs to DNA under physiological
conditions can be disfavoured by intracellular potassium
(10–12). High potassium concentrations induce G-rich
oligonucleotides to assume intra-o rinter-molecular
G-quartet structures that subtract the TFO from the
equilibrium of triplex formation, with the result that the
triplex is not observed even at sub-physiological potas-
sium concentrations. This is the reason why most of the
literature data about in vitro triplex formation by G-rich
TFOs have been obtained in the absence of potassium.
One therefore wonders if the antigene activity reported by
certain G-rich oligonucleotides is really mediated by
triplex formation at the corresponding target site. In
order to potentiate the capacity of TFOs to form stable
triplexes in the cellular context, several chemical modiﬁca-
tions at the sugar phosphate backbone have been
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tide nucleic acids (13–15), locked nucleic acids (16,17),
20-aminoethyl oligoribonucleotides (18) and N30-P50 phos-
phoroamidites (19). Stabilization of triplex DNA has also
been obtained by linking the 50 or 30 end of TFOs to an
intercalator, a modiﬁcation that can enhance the Tm of
parallel triplexes up to 168C (20–25). However, little is
known about the eﬀect on triplex formation of inter-
calators inserted as a bulge in the middle of the TFO
sequence. This type of modiﬁcation has been recently
tested in TFOs forming CT-motif parallel triplexes (26).
Bulged insertions of (R)-1-O-[4-(1-pyrenylethynyl) phe-
nylmethyl] glycerol inside CT-TFOs (with a cytosine
content up to 36%) were found to form stable parallel
triplexes, whereas unmodiﬁed TFOs were not able to bind
to the target (27). Molecular modelling with MacroModel
8.0 showed that both pyrene and phenyl are twisted
around the triple bond with a torsion angle of about
15.3 degrees (27). This suggested that twisting helps the
intercalator unit to adjust within the target duplex, so that
the parallel triple helical complex is signiﬁcantly stabilized.
The study of Filichev et al. represents a new development
in triplex technology, but the concept of pyrene bulge
insertions was only applied to CT-motif parallel triplexes,
as well as to non-natural target sequences. We therefore
wondered what eﬀect pyrene bulge insertions might have
on triplex formation by purine-motif TFOs, capable to
form antiparallel triplexes with natural and therapeutically
important targets. Here, we addressed two main ques-
tions: (i) do purine twisted-intercalating TFOs form stable
triple helices in the antiparallel reverse-Hoogsteen con-
formation?; (ii) do G-rich twisted intercalating TFOs
self-associate into quadruplex structures and subtract
themselves from the interaction with duplex DNA? To
answer these questions we designed twisted-intercalating
TFOs for two natural pur/pyr sequences present in the
regulatory region of human and murine KRAS genes. The
results obtained show that bulge insertions stabilize triplex
DNA and provide a strategy to overcome potassium-
induced self-aggregation phenomena of G-rich TFOs that
severely limits triplex formation under physiological
conditions. All the data collected in this study point to
the potential of purine twisted-intercalating TFOs as
antigene molecules in cancer therapy.
MATERIALS AND METHODS
Synthesis andpurification of TINA oligonucleotides
The TINA oligonucleotides shown in Figure 1 were syn-
thesized in a 0.2mmol scale on an Expedite
TM Nucleic
Acid Synthesis System Model 8909 from Applied
Biosystems using 4,5-dicyanoimidazole as an activator.
Increased deprotection time (100s) and coupling time
(2min) for 0.075M solution of TINA phosphoramidite
(28) in a 1:1 mixture of dry MeCN/CH2Cl2 was applied.
To obtain phosphorthioates, a freshly prepared 0.0225M
solution of 3-amino-1,2,4-dithiazole-5-thione in dry mix-
ture of pyridine (10%, v/v) and CH3CN was used in a
sulfurization step (29), which was repeated twice for 1min
instead of oxidation step. Use of the solution, which was
3 days old, resulted in an unsuccessful synthesis. The
oligonucleotides were cleaved oﬀ were cleaved oﬀ from the
solid support (room temperature, 2h) and de-protected
(558C, overnight) using 32% aqueous ammonia (1ml).
Puriﬁcation of 50-O-DMT-on ONs was accomplished
using a reverse-phase semi-preparative HPLC on Waters
Xterra
TM MS C18 column. After evaporation of the
solvent on a speed-vac, ONs were treated with 80% aq
AcOH (100ml) for 25min, diluted with 1.5M aq NaOAc
(150ml) and precipitated from EtOH (550ml). Solutions
were kept in a freezer for 1h, centrifuged, decanted and
the precipitate was washed with EtOH and dried. The
modiﬁed ONs were conﬁrmed by MALDI-TOF analysis
on a Voyager Elite Biospectrometry Research Station
from PerSeptive Biosystems [calculated and experimental
MW values are: 1037 (7892.5/7892.0); 1451 (7892.5/
7892.2); 1452 (7425.1/7428.2); 1453 (7876.5/7877.0); 1454
(7409.1/7410.2), 1455 (7876.52/7876.0); 1456 (7676.52/
7677.5); 1457 (7209.12/7210.1); 2218 (7828.2/7829.7)].
The purity of the ﬁnal TFOs was checked by ion-exchange
chromatography using LaChrom system from Merck
Hitachi on GenPak-Fax column (Waters) and found to
be over 90%.
Plasmids. Plasmid pKRS-413, used for the transient
transfection experiments, was kindly gifted by D. George
(University of Pennsylvania). This plasmid, whose struc-
ture has been previously described, is derived from the
chloramphenicol acetyltransferase (CAT) vector
pSVAOcat, in which a 380-bp segment of the KRAS
promoter has been cloned. This construct is able to drive
CAT transcription in host cells. In addition, plasmid
pTKbgal, containing the b-galactosidase gene driven by
the thymidine kinase promoter, was used to evaluate the
transfection eﬃciency. The construction of the mutant
plasmid (pKRS-413-4mut) was done as follows: 75ng of
plasmid pKRS-413 were ampliﬁed in a PCR reaction with
1.25 units of AccuPrime
TM Pfx DNA Polymerase, in a
25ml volume containing  1 AccuPrime
TM Pfx reaction mix
as indicated by the manufacturer (Invitrogen, Milan,
Italy). The primers used are Mut 42, 50-TGCAGCCGC
TCCCTCTCTCTCTCCTTCTCTCTCTCCCGCGCG-30,
with four C-to-T substitutions (bold in Figure 9b) and Mut
25, 50-GAGGGAGCGGCTGCAGCGCTGGGAG-30
(GeneTailor
TM Site-Directed Mutagenesis System, Invi-
trogen, Milan, Italy). The primers are partially overlapping
and were used at a concentration of 100nM. The PCR
reaction was carried out according to the following
protocol: 20 at 958C, 25 cycles each comprising a
denaturation of 30s at 958C, annealing of 30s at 688C,
elongation of 5min at 688C. The ﬁnal cycle was performed
with an elongation step of 10min at 688C. Competent
bacteria were transformed with 7.5ml of PCR product. The
mutant plasmid was sequenced to conﬁrm the introduction
of the mutations.
EMSA. Mobility-shift experiments were performed with
39-mer mouse and 32-mer human critical KRAS promoter
targets. For the preparation of mouse 39-mer duplex 30
pmole of pyrimidine strand was labelled with [g-P
32]ATP
and T4 polynucleotide kinase, then the duplex was
Nucleic Acids Research, 2008, Vol. 36, No. 10 3495prepared by annealing with the purine complementary
strand and 100mM NaCl (10min at 958C and overnight
at room temperature). Human 32-mer duplex was
prepared by labelling the pyrimidine strand in the same
way as mentioned previously. A ﬁxed amount of  10nM
labelled 39-mer mouse duplex or 32-mer human duplex
was mixed with increasing concentrations of mouse TFOs
(mTFOwt, 1037, 1451, 1452 and control 1456) or human
TFOs (hTFOwt, 1453, 1454, 1455 and control 1457), in
50mM Tris–HCl, pH 7.4, 50mM KCl, 10mM MgCl2 and
2mM spermidine (binding buﬀer) and incubated over-
night at 378C. After incubation, the samples were imme-
diately loaded in 15% native polyacrylamide gel prepared
in TB1x and performed at 378C with a ﬁxed voltage of
200V for 5h. After running, the gel was dried and exposed
to autoradiography (Hyperﬁlm, Amersham Biosciences)
for few hours. Wild-type and twisted-intercalating TFOs
(10mM) were analysed in a 15% TBE gel at 208C which
was stained with the stains-all dye. Electrophoresis
mobility shift assays (EMSA) with nuclear extract from
NIH 3T3 and Panc-1 cells were performed with labelled
mouse 39-mer and human 32-mer duplexes. Two proto-
cols have been followed. In one case, the triplexes were
allowed to form overnight at 378C in binding buﬀer before
the protein extract was added and the resulting mixtures
incubated for 2h. In the other case, TFO and protein
extract were added simultaneously to the target duplex
and mixtures incubated for 2h. The protein extract was
equilibrated in 20mM Tris–HCl, pH 8, 30mM KCl,
10mM MgCl2, 1mM DTT, glycerol 8%, Phosphatase
Inhibitor Cocktail I (Sigma) 1%, 5mM NaF, 1mM
Na3VO4, 2.5nM poly dIdC. After incubation, the
mixtures were immediately loaded in 5% TBE  1 native
polyacrylamide gel, with the temperature ﬁxed at 208C.
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5 ’CAGCGCTGCAGCCGCTCCCTCCCTCCCTCCTTCCCTCCCTCCCGCGCGCGCGGCCG
3 ’GTCGCGACGTCGGCGAGGGAGGGAGGGAGGAAGGGAGGGAGGGCGCGCGCGCCGGC
5’-AGGGAGGGAGGGAGGAAGGGAGGGAGGG mTFOwt
5’-agGGAggGAGGAAggGAGgg mTFOwt-S
5’-agGGAggGAGGAAggGAGgg 1037
5’-agGGAggGAGGAAggGAGgg 1451
5’-agGGAggGAGGAAggGAGgg 1452
5’-agCGccAGAAGcgAGAACgg 1456
5’-AGGGGGAGAAGGGAGAAGGG hTFOwt
5’-agGGggAgaAGggAGAAggG hTFOwt-S
5’-agGGggAGAAGggAGAAGgg 1453
5’-agGGggAGAAGggAGAAGgg    1454
5’-agGGggAGAAGggAGAAGgg 1455
5’-agCGggAGAAGcgAGAACgg 1456
5’-acCGcgAGAAGccAGAAGgg 1457
Murine target 
Human target
5’GCCGGCGCTCGCTGCCTCCCCCTCTTCCCTCTTCCCACACCGCCCTCAGCCGCTCCC
3’CGGCCGCGAGCGACGGAGGGGGAGAAGGGAGAAGGGTGTGGCGGGAGTCGGCGAGGG
Figure 1. Pur/pyr motifs present in a regulatory element of the mouse and human KRAS promoters. The sequences of the designed wild-type and
twisted-intercalating TFOs are reported. Bulge insertions of (R)-1-O-[4-1-(1-pyrenylethynyl)-phenylmethyl]glycerol (TINA) have been placed between
the underlined bases of the TFOs. Lower case letters indicate the bases that are linked with a thioate group to make the TFOs resistant to
endogenous nucleases. The structure of the TINA intercalating unit is reported.
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The duplex-to-triplex equilibrium can be written as:
T , TFO þ D 1
where D and T are the duplex and triplex species. This
equilibrium is governed by a dissociation constant Kd
given by:
Kd ¼
ð½TFO  ½ D Þ
½T 
2
We can deﬁne the fraction of triplex fT in the reaction
mixture as:
fT ¼
½T 
ð½D þ½ T Þ
3
Combining Equations (2) and (3) it is obtained that:
fT  
½TFO T
ð½TFO T þ KdÞ
4
As in each reaction mixture, the TFO concentration is
always in excess over the target duplex D, the equilibrium
concentration [TFO] can be reasonably approximated to
the total concentration [TFO]T. Equation (4) has been
used to ﬁt the experimental fT versus [TFO]T plot, using a
nonlinear best-ﬁt program (Marquardt program, Jandel
Scientiﬁc). The fT values have been measured experimen-
tally from electrophoretic titrations, quantifying bands D
and T with an Image Quant TL V2003.03 apparatus
(Amersham Biosciences). The free energy of reaction (1)
was obtained from the general equation
G
o ¼  RT ln K
Circular dichroism. CD spectra were obtained using a
JASCO J-600 spectro-polarimeter equipped with a ther-
mostatted cell holder. The oligonucleotides used for the
CD experiments were at a concentration of 3mM, in
50mM Tris–HCl, pH 7.4 and 100mM KCl. Spectra were
recorded in 0.5cm quartz cuvette. A thermometer placed
in the cuvette holder allowed a precise measurement of the
sample temperature. The spectra were calculated with
J-700 Standard Analysis software (Japan Spectroscopic
Co., Ltd) and are reported as ellipticity (mdeg) versus
wavelength (nm). Each spectrum was recorded three
times, smoothed and subtracted from the baseline.
Spectrofluorimetry measurements. Fluorescence measure-
ments were performed on a Perkin Elmer spectroﬂuori-
meter. The spectra of TFO or TFO-duplex solutions
were recorded at room temperature in 50mM Tris-HCl,
pH 7.4, 10mM MgCl2. TFO and duplex were used at a
concentration of 0.5mM.
DNase I footprinting. DNase I footprints were performed
with DNA fragments of diﬀerent length. Either the purine
or the pyrimidine strand of a murine 60-mer duplex was
end-labelled with [g-
32P]ATP and T4 polynucleotide
kinase, PAGE puriﬁed and annealed with the comple-
mentary cold strand. The labelled target and the TFOs
were pre-incubated, at diﬀerent ratios, overnight in 50mM
Tris-HCl, pH 7.4, 50mM KCl, 10mM MgCl2 and 2mM
spermidine and digested with DNase I: 1ml of a solution
containing 0.001mg/ml DNase I, 50mM Tris-HCl, pH
7.4, 0.1mg/ml BSA, 30mM MnCl2. The reaction was
conducted in a ﬁnal volume of 10ml, for 1min at room
temperature, and stopped by adding to the reaction
mixture 10ml of stop solution (90% formamide, 50mM
EDTA, bromophenol blue). Experiments with the murine
target were also conducted with a DNA of 153bp, which
was obtained from plasmid pKRS-413 digested with Not I
and Ava I. In this case we labelled the purine strand using
[a-P
32]CTP and Klenow fragment. A standard Maxam-
Gilbert G reaction was carried out in order to identify the
TFO binding site. DNase I footprinting with the human
target were performed with a 79-mer duplex labelled at the
purine strand with [g-P
32]ATP and the T4 polynucleotide
kinase. The digested DNA was heated for 10min at 978C
and loaded in 18% polyacrylamide gel in TBE  1 (50mM
Tris base, 50mM Boric acid, 1mM EDTA) and 8M urea,
pre-equilibrated at 558C in a BioRad Sequi-Gen GT
nucleic acids electrophoresis apparatus, which was
equipped with thermocouple allowing temperature con-
trol. After running, the gels were ﬁxed in a solution
containing 10% acetic acid, 10% methanol, dried at 808C
in a Bio-Rad dryer and exposed to autoradiography
(Hyperﬁlm, Amersham Biosciences) at –808C for few
hours.
CAT assay. NIH 3T3 cells were transfected with mixtures
containing plasmid pKRS-413 (or mutant pKRS-413-
4mut), containing the CAT reporter gene driven by the
murine KRAS promoter, plasmid pPTK-bgal to deter-
mine transfection eﬃciency, and a speciﬁc oligonucleotide.
The transfections were performed using jet-PEI as trans-
fecting agent. Forty-eight hours after transfection the cells
were washed three times with PBS. The cells were then
lysed with MOPS containing 0.1% Triton X-100, pH 6.5.
Protein extracts were obtained and used for the CAT and
b-gal assay using a commercial ELISA kit (Boehringer
Manheim, Germany). A volume of 200ml of protein
extract was incubated in each well of the plate coated with
the anti-CAT antibody linked to digoxygenin for 1h. The
plate was washed and incubated with anti-digoxygenin
antibody conjugated to peroxidase enzyme. Finally, the
peroxidase substrate was added to the reaction mixture.
The reaction catalyzed by peroxidase gave a green colour
that was quantiﬁed by optical density. For the b-gal
procedure a similar assay was performed.
Molecular modelling. Molecular modelling was performed
with MacroModel v7.5 from Schro ¨ dinger. All calculations
were conducted with AMBER
  force ﬁeld and the GB/SA
water model. The dynamic simulation was preformed with
stochastic dynamics, a SHAKE algorithm to constrain
bonds to hydrogen, time step of 1.5 fs and simulation
temperature of 300K. Simulation for 0.5ns with an equil-
ibration time of 150 ps generated 250 structures, which
were all minimized using the PRCG method with con-
vergence threshold of 0.05kJ/mol. The minimized struc-
tures were examined with Xcluster from Schro ¨ dinger,
Nucleic Acids Research, 2008, Vol. 36, No. 10 3497and arepresentative low-energy structure was selected. The
starting structure was generated from an NMR-based
antiparallel triplex (downloaded from www.rcsb.org/pdb;
PDB ID: 134d, 30) which was modiﬁed into a truncated
1037 antiparallel triplex.
RESULTS
Targets anddesign of TINA–TFOs
As target for the TFOs in this study we chose a perfect
pur/pyr motif present in the promoter of the KRAS proto-
oncogene. This sequence, which is conserved in human
and mouse is essential for transcription, as its excision
results in a strong decline of gene expression (31–33)
(Figure 1). Previously we tried to knock down the human
KRAS gene by TFOs conjugated to the 50 end to
polyethylene glycol, but the results we obtained were not
satisfactory (34). In the present study we have introduced
covalent modiﬁcations in the middle of the TFO sequence
in the form of bulge insertions of (R)-1-O-[4-1-(1-
pyrenylethynyl) phenylmethyl] glycerol: this is an inter-
calating unit composed by a pyrenylethynyl moiety
attached to the end of a ﬂexible phenyl methyl glycerol
arm (Figure 1). In previous molecular modelling studies
on pyrimidine motif triplexes we have shown that the
intercalator, due to its ﬂexible phenylmethyl glycerol
arm, twists around the triple bond and nicely ﬁts inside the
triplex. The TFO was therefore called ‘twisted- intercalat-
ing nucleic acid’ (TINA) (27). In the present work we have
extended the design of twisted-intercalating TFOs to
G-rich oligonucleotides forming reverse-Hoogsteen anti-
parallel triplexes with C+G rich targets. It is known that
triplex formation by G-rich TFOs depends on two
variables: the sequence of the target and the tendency of
TFOs to self-associate or fold into quadruplex structures,
in particular in the presence of physiological levels of
potassium (35,36). We therefore reasoned that bulge
insertions of pyrene units should stabilize antiparallel
triplexes, as already observed for parallel triplexes (27),
but at the same time they should inhibit TFO self-
association. Indeed, according to molecular modelling,
TINA–TFOs with two or three bulge intercalating units
are expected to bind to duplex DNA giving rise to a
compact and stacked triplex, but they can hardly self-
associate in an intermolecular quadruplex by accommo-
dating 8/12 intercalators. As proof of concept we designed
twisted intercalating TFOs for a regulatory pur/pyr
element in the KRAS promoter. We considered the
pur/pyr sequences present in both murine and human
promoters and designed for these targets 20-mer TFOs
with two or three pyrene bulge insertions, diﬀerently
distributed along the TFO sequence. These insertions have
been put either inside the guanine runs (1037, 1453, 1454)
or outside/adjacent to them (1451, 1452, 1455). In
addition we designed 20-mer control oligonucleotides
with pyrene bulge insertions (1456 and 1457), where
some guanines were substituted by cytosines. To make the
designed TFOs resistant to endogenous nucleases, one
oxygen was replaced by sulphur in four internucleotide
phosphate groups of each conjugate (Figure 1)
Triplex formation by G-rich TINA–TFOs in thepresence
of potassiumions
The binding to the KRAS targets of the designed wild-type
and TINA TFOs was studied by EMSA. Figure 2 shows
EMSA titrations performed in 50mM Tris–HCl, pH 7.4,
50mM KCl, 10mM MgCl2, 2mM spermidine (binding
buﬀer). TFOs and target duplex were incubated overnight
at 378C in the binding buﬀer and the mixtures separated
by 15% polyacrylamide gels, thermostated at 378C. It can
be seen that both murine and human wild-type TFOs did
not practically bind to the corresponding targets, whereas
TINA–TFOs showed binding, although the oligonucleo-
tides have a G content as high as 65–70%. From
electrophoresis titrations we determined for each TFO
the Kd as described in Materials and Methods. The values
obtained (Table 1) are of the order of 10
–7M, except for
1452 which showed a higher Kd. There seems to be a
correlation between triplex formation and the number of
TINA insertions in the TFO: the human TFO 1454 with
two bulge insertions shows a higher target aﬃnity than
1453 which has one more bulge insertion than 1454,
between an AA dinucleotide. This suggests that the
accommodation of three TINA intercalating units in a
20-mer triplex may cause some distortion and destabiliza-
tion to the structure. The fact that controls 1457 and 1456
(containing respectively two and three bulge insertions) do
not bind to the target suggests that the TINA–TFOs
maintain the sequence speciﬁcity typical of triplex DNA.
To evaluate if potassium concentrations higher than
50mM might inhibit triplex formation by the TINA–
TFOs, we performed EMSA experiments in which lithium
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Figure 2. Electrophoretic mobility shift assays showing triplex forma-
tion at 378C in 50mM Tris–HCl, pH 7.4, 50mM KCl, 10mM MgCl2
and 2mM spermidine (binding buﬀer). Experiments were performed
with [g-
32P]ATP-labelled 39-mer murine duplex (5nM) and 32-mer
human duplex (15nM) of the KRAS gene. Increasing concentrations of
TFOs (as indicated) were mixed with the target duplex and incubated
overnight in the binding buﬀer at 378C. The mixtures were run at 378C
in a 15% native polyacrylamide gel.
3498 Nucleic Acids Research, 2008, Vol. 36, No. 10was gradually replaced by potassium, while the total ion
concentration was kept constant at 140mM. Figure 3
shows a typical experiment performed with murine 1037
and wild-type mTFOwt. It can be seen that mTFOwt binds
to the target in the presence of 140mM LiCl. By just
adding 10mM KCl, triplex formation by the wild-type
sequence is almost completely abrogated. Oligonucleotide
1037 with three TINA insertions in its sequence also binds
to the target in 140 LiCl, but its binding does not decrease
as lithium is gradually replaced by potassium, keeping
the total ionic strength of the solution ﬁxed at 140mM
(Figure 3b). This experiment shows that twisted-intercalat-
ing TFOs, contrarily to wild-type analogues, are less prone
to self-aggregation in the presence of potassium. In order
to gain more evidence for this behaviour we analysed the
electrophoretic mobility and the CD spectra of the wild-
type and twisted-intercalating TFOs. The oligonucleotides
(10mM) were incubated overnight in 50mM Tris–HCl,
pH 7.4, 100mM KCl, 378C and analysed by a native
15% PAGE (Figure 4a). It can be seen that whereas
mTFOwt migrated with a strongly retarded band due to
self-aggregation, the TINA analogues 1037, 1451, 1452
migrated mainly as a single-stranded species. Note that
TINA–TFOs also form aggregates, but to a much lower
extent than mTFOwt. The aggregates of the murine TFOs
are likely to be intermolecular G4-DNA structures.
Indeed, DMS-footprinting assays show that in 100mM
KCl, but not in 100mM LiCl, the guanines of mTFOwt,
except those of the central GG couple, are protected from
cleavage. Thus, PAGE and DMS probing suggest the
formation of a concatenamer of 6–8 strands in which the
runs of three guanines form the G-tetrads. In addition to
the concatenamers, it is possible that some mTFOwt folds
into an intramolecular G4-DNA (Supplementary Data
S1A). In contrast, murine TINA TFOs do not show any
footprinting in KCl, in accord with a lower aggregation.
A typical DMS-footprinting for 1037 is shown in Supple-
mentary Data S1B. As for human wild-type hTFOwt,
it showed a mobility comparable to that of a 32-mer
duplex, indicating that this oligonucleotide either assumes
a homoduplex or, more likely, a folded bimolecular
G-quadruplex (Supplementary Data S2). TINA deriva-
tives 1453, 1454 and partly 1455 migrate as 20-base species,
indicating that they do not aggregate in the potassium
containing medium. The resistance to aggregation of 1453
and 1454 can be ascribed to the pyrenyl intercalators,
which in these oligonucleotides have been put inside the
guanine runs, disrupting the G-motif and preventing the
formation of G-quartet structures. So the electrophoretic
analysis corroborates the working hypothesis raised in
this study according to which, contrarily to wild-type
sequences, TINA–TFOs bind to the KRAS target in the
presence of potassium because they are not inclined
to aggregation. Further data suggesting that twisted-
intercalating TFOs undergo little self-association in KCl
were obtained by circular dichroism. It is known that
potassium and, to a lesser extent, sodium induce G-rich
oligonucleotides to form a variety of structures including
GG duplexes and G-quartets (36,37). The designed TFOs
were analysed by CD: the wild-type sequences exhibited
a strong positive ellipticity at 260nm and a negative
ellipticity at 240nm, which suggests either a GG homo-
duplex (37) or a parallel G-quadruplex (38,39). In contrast,
TINA analogues 1037 and 1454 showed a signiﬁcantly
weaker ellipticity at 260nm, suggesting that they are
slightly associated in the potassium buﬀer (Figure 4b).
Plotting the 260nm ellipticity as a function of tempe-
rature we obtained cooperative curves from which we
evaluated Tm’s of 718C and 558C for the putative murine
concatenamer and human bimolecular G-quadruplex,
respectively.
Footprintingstudies
Considering that the pyrenyl units strongly favour triplex
formation by the TINA–TFOs, one could argue that the
stabilization may reduce the sequence binding speciﬁcity.
To address this question we performed DNase I footprint-
ing experiments under diﬀerent ionic conditions. First,
we analysed in detail triplex formation between the murine
KRAS target, mTFOwt and TINA analogue 1037.
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Figure 3. Eﬀect of lithium and potassium on triplex formation at the
pur/pyr element of murine KRAS promoter. Oligonucleotides mTFOwt
(panel a) and 1037 (panel b), were incubated at 378C with murine
39-mer duplex (5nM) in 50mM Tris–HCl, pH 7.4, 10mM MgCl2,
2mM spermidine and 140mM monovalent cations at various lithium/
potassium ratios. The mixtures were incubated overnight at 378C in the
speciﬁc buﬀer and run (at 378C) in a native 20% polyacrylamide gel.
Table 1. Thermodynamic parameters for duplex–triplex equilibrium in
50mM Tris-HCl, pH 7.4, 50mM KCl, 10mM MgCl2,2 m M
spermidine, 378C, relative to human and murine KRAS duplexes and
TINA-TFOs
Oligonucleotide Triplex Kd (M) G
37 a (kcal/mol)
mTFOwt No – –
1037 Yes 8.3 10
 7  8.6 0.4
1451 Yes 3.4 10
 7  9.2 0.2
1452 Yes 2.6 10
 6  7.9 0.2
1456 No – –
hTFOwt No – –
1453 Yes 6.1 10
 7  8.8 0.1
1454 Yes 1.3 10
 7  9.8 0.1
1455 Yes 8.7 10
 7  8.6 0.1
1457 No – –
aUncertainty estimated by the Marquardt non-linear best-ﬁt program.
Nucleic Acids Research, 2008, Vol. 36, No. 10 3499Figure 5 shows the footprinting obtained by labelling
either the purine or the pyrimidine strand of a 60-mer
DNA duplex spanning over the murine pur/pyr sequence.
To identify the TFO binding site, a standard Maxam-
Gilbert G reaction was performed with the G strand of the
target. In accord with EMSA it was found that mTFOwt
(5mM) did not bind to the target in the presence of 50mM
KCl (lane 3, R strand labelled). Instead, oligonucleotide
1037 saturated all the target sites by triple-helix formation
at 2 and 5mM (lanes 4, 5). When the pyrimidine strand of
the target was end labelled with
32P, a similar result was
obtained, with the diﬀerence that the target site was now
observed near the 50 end of the 60-mer duplex. In this case
too, mTFOwt did not bind to duplex DNA in the presence
of potassium, whereas 1037 did the binding at both
concentrations. In order to test the binding speciﬁcity of
all the designed murine TINA–TFOs, we performed
footprinting experiments with a 153-mer duplex in the
presence of 50mM sodium or potassium ions. In NaCl we
observed that both wild-type and TINA–TFOs bound to
the target (Supplementary Data, S3). Instead, in 50mM
KCl the wild-type mTFOwt did not appreciably bind to
the target, while the three TINA–TFOs 1037, 1451 and
1452 did (Figure 6a). As expected, control sequences 1457
and 1456 with three and two pyrene insertions, respec-
tively, did not protect duplex DNA from DNase I even at
the concentration of 5mM. It is worth noting that 1452,
despite it is characterized by a less favourable Go f
binding, seems to protect the target more eﬃciently than
1037 and 1451. This is probably due to a lower tendency
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Figure 4. (a) Native polyacrylamide gel of wild-type and TINA–TFOs. TFOs (10mM) were incubated overnight at 378C in 50mM Tris–HCl, pH 7.4,
100mM Kcl and run in a native 15% PAGE. The gel was stained with ‘stains all’ dye. (b) Circular dichroism spectra of murine mTFOwt, 1037 and
human hTFOwt, 1454 at increasing temperatures from 258Ct o9 5 8C. All samples were used at the concentration of 3mM, incubated overnight in
50mM Tris–HCl, pH 7.4, 100mM KCl before the analysis. The CD spectra of 1037 and 1454 in 100mM LiCl are similar to those reported in the
ﬁgure.
3500 Nucleic Acids Research, 2008, Vol. 36, No. 10of 1452 to aggregate at 5mM (Figure 4a). Footprinting
studies carried out with the human target gave similar
results: hTFOwt and TINA analogues 1453, 1454 and
1455 eﬃciently bound to duplex DNA in the presence of
50mM NaCl (Supplementary Data S4), whereas only the
TINA analogues showed strong binding in the presence of
50mM KCl (Figure 6b). In conclusion, footprinting and
EMSA demonstrate that TINA–TFOs are able to bind to
duplex DNA in the presence of 50mM KCl in a sequence-
speciﬁc manner while the wild-type analogues do not have
that capacity.
Molecular modelling studies
Structural calculation (MacroModel) of triplex DNA with
TINA oligonucleotides as third strand shows that the
pyrene moiety intercalates in the Watson–Crick duplex
portion of the structure while the phenyl in the phenyl-
methyl glycerol arm is coaxial with the nucleobases of the
third strand (Figure 7a and b). Thereby the TINA–
monomer is mimicking the spatial void from a base triplet
and adds to the triplex stability by stacking interactions.
But as opposed to a base triplet the covalently bound
pyrene moiety may anchor the TFO to the duplex resulting
in a higher stability. It was also found that the intercalator
twists around the triple bond by 1–10 degrees in the
antiparallel triplex, depending on the structure selected
from the cluster analysis, compared to 15.3 degrees for the
monomeric structure (27), showing the intercalators’
ability to adjust secondary structural changes in order to
attain an optimal ﬁt. It was found that, unlike the TFO-
backbone in the parallel triplex, the TFO-backbone in the
antiparallel triplex was positioned in the middle of the
major groove relative to the backbones of the duplex. This
secondary structural property of the antiparallel triplex
decreases the electrostatic repulsion between the negatively
charged backbones, which is considered to be one of the
main obstacles for the formation of the parallel triplex (40).
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Figure 5. DNase I footprinting showing the binding of murine
mTFOwt and 1037 to a 60-mer target duplex (D) spanning over the
pur/pyr motif (20nM), in which either the purine or the pyrimidine
strand was labelled with [g-P
32]ATP and polynucleotide kinase. Lanes 1
and 6, Maxam-Gilbert G-reaction of D; lanes 2 and 10, DNase I
digestion of D; lanes 3 and 7, digestion of D in the presence of 5mM
mTFOwt; lanes 4, 5 and 8, 9, D digestion in the presence of 2 and 5mM
1037. In lanes 2–5, D was labelled at the purine strand; in lanes 7–10, D
was labelled at the pyrimidine strand. In this experiment we used a
wild-type mTFOwt of 28nt. The bases of 1037 in read indicate the
position of the TINA intercalators.
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Figure 6. (a) DNase I footprinting showing the binding of murine
TFOs 1037, 1451, 1452 to a 153-mer duplex obtained from the murine
promoter labelled at the purine strand with [a-P
32] CTP and Kleenow
fragment. Target digestion in the absence of TFO (lane 1), in the
presence of 5mM mTFOwt (lane 3), 1037 (lane 4), 1451 (lane 5), 1452
(lane 6), control 1456 (lane 7), control 1457 (lane 8). A G-reaction with
the target duplex is shown in lane 2; (b) DNase I footprinting showing
the binding of human TFOs 1453, 1454 and 1455 to a 79-mer human
duplex labelled at the purine strand with [a-P
32]ATP and polynucleo-
tide kinase. Target digestion in the presence of 3mM hTFOwt (lane 1),
1453 (lane 2), 1454 (lane 3), 1455 (lane 4), 1457 (lane 5). Lane 6 shows
the digestion of the 79-mer target duplex. The footprints have been
performed in 50mM Tris–HCl, pH 7.4, 50mM KCl, 10mM MgCl2,
2mM spermine (binding buﬀer). The same experiment was performed
with the TFOs at the concentration of 5mM and similar results were
obtained (Supplementary Data S5).
Nucleic Acids Research, 2008, Vol. 36, No. 10 3501An indication that pyrene does intercalate into the
double helix portion of the triplex was obtained by
ﬂuorescence experiments. When TINA-conjugated oligo-
nucleotides are excited at 340nm, a characteristic ﬂuores-
cence spectrum with maxima at 400 and 421nm is usually
observed. We observed that the formation of antiparallel
triplexes by guanine-rich TINA–TFOs with a 39-mer
murine duplex resulted in ﬂuorescence quenching. A
typical quenching eﬀect obtained by adding to a solution
of oligonucleotide 1037 the 32-mer murine duplex is
reported in Figure 7c. This is in keeping with the previous
ﬁnding that the presence of guanine next to the pyrene
induces ﬂuorescence quenching (41). This result supports
the conclusion from molecular modelling that pyrene is
intercalated in the duplex portion of the structure.
DNA–protein interaction: competition experiments
As the pur/pyr motif of KRAS used as target for the
designed TINA–TFOs is a regulatory transcriptional
element, we have searched for putative transcription
factors binding to this critical sequence by using a com-
puter program from Geno Matix, MatInspector (www.
genomatix.de). It was found that the KRAS promoter
region spanning over the pur/pyr motif should be
recognized by three zing ﬁnger transcription factors:
ZF5F, MZF1, ZBPF. There is indeed a high sequence
homology (>90%) between the pur/pyr element and the
consensus sequence of these proteins. When the 32-mer
duplex corresponding to the human pur/pyr motif is
incubated with nuclear extract, one main DNA–protein
complex is observed by EMSA (Figure 8a). As this
complex is competed away by excess unlabelled pur/pyr
duplex but not by unrelated DNA duplexes (17-mer
duplex with the Sp1 motif and DNA from plasmids
pSVCAT, pTK-bgal), we concluded that the pur/pyr motif
is bound by the nuclear proteins in a sequence-speciﬁc
manner (data not shown). We have not yet identiﬁed the
proteins present in this DNA–protein complex; however,
they could be indeed by the abovementioned zing ﬁnger
transcription factors. In order to see if the designed
twisted-intercalating TFOs are able to block the binding
of the nuclear factors to the regulatory pur/pyr motif, we
performed competition experiments. Figure 8a shows that
when the TINA–TFOs 1453, 1454 and 1455 are bound to
the human pur/pyr sequence, they prevent the formation
of the DNA–protein complex. As the nuclear extract
contains 140 mM KCl, both wild-type hTFOwt and
control TINA oligonucleotide 1457 did not abrogate
protein binding. When the experiment was carried out
with a higher TFO concentration (5mM), the inhibition by
the TINA TFOs was even stronger while hTFOwt was still
found unable to inhibit protein binding. To rule out the
possibility that the abrogation of the DNA–protein
complex is due to direct binding of the TINA TFOs to
the proteins, rather than being due to triplex formation,
we labelled 1453, 1454 and 1455 with
32P, incubated them
with crude extract and found that they did not bind to any
protein (not shown). EMSA experiments were also carried
out with the murine 39-mer pur/pyr duplex and crude
extract from murine NIH 3T3 cells (Figure 8b). Also in
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Figure 7. (a, b) Calculated structures obtained by molecular modelling
showing the intercalation of the pyrene moiety within the double helical
portion of the triplex and the stacking of the phenyl between the
nucleotides of the third strand (TFO); (c) Fluorescence spectra in
50mM Tris–HCl, pH 7.4, 100mM KCl of 500nM 1037 (a), 500nM
1037+500nM 39-mer murine duplex (b), 500nM 1037+1000nM
39-mer murine duplex.
3502 Nucleic Acids Research, 2008, Vol. 36, No. 10this case we observed the formation of a DNA–protein
complex. As happens with the human pur/pyr sequence,
this complex did not form when the target was previously
treated with the designed TINA TFOs 1037, 1451 and
1452. Instead, oligonucleotides hTFOwt, 1456 and 32deg
did not interfere with protein binding, as is to be expected.
We also investigated whether adding simultaneously TFO
and extract to the DNA target, still results in the
abrogation of the DNA–protein complex. Figure 8c
shows that 1037, 1051 or 1052 (3mM) are able to block
the binding of the protein to the DNA target even when all
the reagents are mixed in the reaction tube at the same
time. Taken together these data provide strong evidence
that the designed twisted-intercalating TFOs are able to
block the binding of nuclear factors to a transcription
regulatory pur/pyr element located in the promoter of the
KRAS gene.
Transient transfection experiments
As the designed TINA–TFOs eﬃciently block protein
binding to the regulatory pur/pyr motif of the KRAS gene
which is essential for transcription, we investigated their
capacity to down-regulate the activity of KRAS in NIH
3T3 cells. The cells were transfected with mixtures
containing plasmid pKRS-413 (2mg), bearing the CAT
gene driven by the murine KRAS promoter, and either a
TFOs or a control oligonucleotide (1mM). In the
transfection mixtures we also added plasmid PTK-bgal
(50ng) to evaluate transfection eﬃciency. The mixtures
were transfected in NIH 3T3 cells by using a commercial
polyethylenimine liposome. To quantify the expression of
CAT and b-gal, we performed immunoassays with anti–
CAT and anti-b-gal antibodies. The residual CAT
expression in NIH 3T3 cells treated with the TFOs or
control oligonucleotides is shown in Figure 9a. It can be
seen that TINA–TFOs 1037, 1451 and 1452 reduced CAT
expression by roughly 50%, whereas mTFOwt and
control TINA-oligonucleotides 1456 and 1457 did not
have any signiﬁcant eﬀect on CAT. Note that 1452 shows
a lower capacity to inhibit CAT expression (40%
inhibition) compared to 1037 (60%) and 1451 (50%), in
keeping with a less favourable G of triplex formation
found for 1452 compared to 1037 and 1051 (Table 1).
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Figure 8. EMSA showing the abrogation by the designed TINA TFOs of a DNA–protein complex C1 formed between the murine and human KRAS
pur/pyr element and a nuclear extract. (a) DNA–protein interaction between a 32-mer human duplex (50-AGGGCGGTGTGGGAAGAGGG
AAGAGGGGGAGG; 50-CCTCCCCCTCTTCCCTCTTCCCACACCGCCCT) and Panc-1 nuclear extract in the presence or absence of TFO.
Loading: human target (10nM) with 3mg extract (lane 1); human target (10nM)+1mM 1453, 1454, 1455, hTFOwt and 1457 incubated overnight at
378C in binding buﬀer (see EMSA), then the mixtures treated with 3mg extract for 2h (lanes 2–6); human target (10nM)+5mM 1453, 1454, 1455
and hTFOwt incubated overnight, then the mixtures treated for 2h with 3mg extract (lanes 7–10); (b) DNA–protein interaction between a 39-mer
murine duplex (50-CGCGCGGGAGGGAGGGAAGGAGGGAGGGAGGGAGCGGCT; 50-AGCCGCTCCCTCCCTCCCTCCTTCC-CTCC-
CTCCCGCGCG) and NIH 3T3 nuclear extract in the presence or absence of TFO. Loading: 39-mer murine duplex (10nM) incubated with
12mg NIH 3T3 extract for 2h (lane 1); 32-mer duplex (10nM)+1mM mTFOwt; 1037, 1451, 1452, 1456, 32deg incubated overnight in binding buﬀer
at 378C, then treated for 2h with 12mg extract (lanes 2–7); (c) 39-mer murine duplex (10nM) added simultaneously with 12mg NIH 3T3 extract and
3mM 1037, 1451, 1452, 1456, 32deg and incubated for 2h (lanes 3–7); duplex with only 12mg NIH 3T3 extract (lanes 1 and 2). The sequence of 32deg
is: 50-GCATTCTGATTACACGTATTACCTTCACTCCA.
Nucleic Acids Research, 2008, Vol. 36, No. 10 3503To check if the designed TINA TFOs promote aptameric
eﬀects, we introduced four G-to-A mutations in the
murine pur/pyr sequence of plasmid pKRS-413. This
brought about a change in the pur/pyr sequence but not in
its polypurine character (Figure 8b). Despite these
substitutions, the mutant plasmid, pKRS-413-4mut,
maintained a capacity to express CAT. The mutated
pur/pyr element should not be recognized by 1037, 1451
and 1452 TFOs, but by 2218 and by its unconjugated
analogue mTFO-4mut, as these two oligonucleotides have
been designed with a sequence speciﬁc for the mutated
target (Figure 9b). Indeed, EMSA shows that 1037, 1451
and 1452 do not bind to the mutated target, whereas 2218
and mTFO-4mut do (Figure 9c). Contrary to mTFOwt,
5’-TCCCTCCCTCCCTCCTTCCCTCCCTCCC
3’-AGGGAGGGAGGGAGGAAGGGAGGGAGGG
5’-agGGAggGAGGAAggGAGGG   mTFOwt-S
TFO   :  1037, 1451, 1452, mTFOwt-S  
control:  1456, 1457
5’-TCCCTCTCTCTCTCCTTCTCTCTCTCCC
3’-AGGGAGAGAGAGAGGAAGAGAGAGAGGG
5’-agAGAgaGAGGAAgaGAGag     2218
TFO    : 2218, mTFO-4mut
control: 1031, 1451, 1452
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Figure 9. (a) CAT assay to determine the eﬀect of the designed twisted-intercalating TFOs on the activity of KRAS promoter. Plasmids pKRS-413
(2mg), containing CAT driven by the mouse KRAS promoter, and pTK-bgal (50ng) were co-transfected with murine TFOs 1037,1451,1452, mTFOwt
or control 1456 and 1457 (1mM), using jet-PEI. The expression of CAT, with respect to that of b-gal, was determined by an ELISA assay, 48h after
transfection. The percentage of residual CAT expression, [(CAT/b-gal)TFO/(CAT/b-gal)Control] 100, is reported in the histograms. The values are the
average of three independent experiments in duplicate. Error bar are SE; (b) transfection experiment as in (a) but with the mutated plasmid pKRS-
413-4mut in which the KRAS promoter has been mutated at the pur/pyr target introducing 4G-to-A mutations. The mutated target is recognized by
the TINA conjugate 2218 (50-agAGPAgaGAG-GPAAgaGPAGag; P indicates a TINA modiﬁcation; the lower case letters indicate the bases linked
by a phosphorothioate group) and mTFO-4mut (50-AGGGAGAGAGAGAGGAAGAGAGAGAGGG); (c) EMSA showing that triplex formation
occur between the mutated pur/pyr target and TINA–TFO 2218 and mTFO-4mut, but not with the TFOs designed for the wild-type pur/pyr sequence
(mTFOwt, 1037, 1451, 1452). TFOs and target were incubated overnight at 378C in 50mM Tris–HCl, pH 7.4, 50mM KCl, 10mM MgCl2,2 m M
spermidine and run in a native 20% polyacrylamide gel. The mutated duplex was formed mixing 1:1 50-GCTCCCTCTCTCTCTCCTTCTCTC
TCTCCCG and 50-CGGGAGAGAGAGAAGGAGAGAGAGAGGGAGC.
3504 Nucleic Acids Research, 2008, Vol. 36, No. 10the mutant analogue mTFO-4mut binds to the target even
in the presence of potassium, due to its lower G-content
and therefore reduced tendency to aggregate. When
pKRS-413-4mut was transfected with the designed
TINA TFOs (1037, 1451 and 1452) in NIH 3T3 cells, we
did not observe any CAT inhibition. But when it was
transfected with 2218 (with which it forms a triplex), a
CAT inhibition of about 40% was observed. This
experiment indicates that the down-regulation of KRAS
promoted by the designed TINA TFOs is likely mediated
by triple helix formation at the promoter. These data,
together with those obtained by EMSA, footprinting and
DNA–protein interaction assays, suggest that TINA–
TFOs, contrarily to the wild-type TFOs, have a potential
as therapeutic antigene molecules.
DISCUSSION
In a recent study Vasquez and co-workers (1) reported
that about 98% of human genes contain at least one high
aﬃnity TFO target in the promoter or, less frequently, in
the coding region. This suggests that it is in principle
possible to target most human genes with speciﬁc TFOs,
which explains why triplex DNA could be an interesting
approach to manipulate the genome.
However, even if pyrimidine oligonucleotides have been
discovered to form triplex helical complexes at acidic
conditions almost two decades ago, several problems still
remain to be solved, and this limits the use of DNA triplex
technology in vivo. One of the major obstacles is that
triplex formation by G-rich oligonucleotides can be
severely inhibited by physiological potassium concentra-
tions (10–12). This is because TFOs containing guanine
runs tend to self-associate into G-quartet structures
(36,38,42), with the result that they are subtracted from
the duplex-to-triplex equilibrium. Of the two types of
TFOs, CT-oligonucleotides forming parallel Hoogsteen
triplexes and AG/GT-oligonucleotides forming antipar-
allel reverse-Hoogsteen triplexes, the latter have the
potential to bind to duplex DNA under physiological
conditions. Indeed, several research groups have studied
AG/GT oligonucleotides as antigene eﬀector molecules in
the context of anticancer therapy (43–49). But two major
problems, i.e. oligonucleotide self-association and the
susceptibility to endogenous nucleases, have up to now
prevented TFOs from being used as therapeutic agents.
There are several strategies to circumvent self-association
by G-rich oligonucleotides, as reported in the literature:
(i) incorporation of 6-thioguanine in a limited number of
positions within purine oligonucleotides reduces G-quar-
tet formation under physiological conditions, but it also
slightly destabilizes the triplex (10); (ii) replacement of
negative phosphodiester bonds with positively-charged
phosphoramidite linkages may also favour triplex forma-
tion in the presence of KCl (11); (iii) hybridization of the
TFO 30 or 50 ends to a short complementary oligonucleo-
tide has shown to prevent aggregation without aﬀecting
triplex formation (12); (iv) replacement of guanine with
7-deazaguanine eliminates the ability of G-rich oligonu-
cleotides to form Hoogsteen hydrogen-bond between the
2-amino and N7, which is essential for formation of
G-quartets (50,51), but unfortunately the antiparallel
triplex is destabilized due to a change in the atomic
charge pattern (52). Recently, Filichev and Pedersen (27)
have designed a new type of pyrimidine TFO containing
inside its sequence one or two bulge insertions of (R)-1-O-
[4-1-(1-pyrenylethynyl)-phenylmethyl] glycerol; i.e. an
intercalating unit characterized by a ﬂexible phenyl
glycerol linker at the end of which a pyrene molecule is
covalently attached. When bulge insertions were intro-
duced in a parallel Hoogsteen-type CT triplex with a
cytosine content of 36%, triplex formation was even
observed at pH 7.2, whereas the unconjugated analogues
were unable to bind to the target (27). Molecular
modelling showed that the ﬂexible phenylmethyl glycerol
arm places the pyrenyl moiety into the dsDNA part of the
triplex while the phenyl assumes a coaxial position with
the nucleobases of the TFO. A twist around the triple
helical bond allows the phenyl and pyrene to ﬁt properly
inside the triplex, promoting stabilizing stacking interac-
tions. This is clearly illustrated in the structure shown in
Figure 7. In our study this approach has been applied to
antiparallel reverse-Hoogsteen triplex DNA. We discov-
ered that G-rich TINA–TFOs form stable triple helical
complexes under physiological conditions and, more
surprising, that they were resistant to potassium-induced
self-aggregation. We designed TINA–TFOs speciﬁc for a
regulatory pur/pyr site in the murine and human KRAS
genes. As this element is recognized by nuclear factors
essential for transcription, it is an ideal target for TFOs.
The TINA–TFOs were designed with two or three bulge
insertions located either inside or adjacent to the guanine
runs. Electrophoresis mobility-shift and footprinting
experiments showed that twisted-intercalating TFOs, but
not the wild-type analogues, bind to duplex DNA in the
presence of potassium up to 140mM. The diﬀerent
binding behaviour between TINA and wild-type TFOs
correlate with the high tendency of the latter to self-
associate into unusual G-quadruplex structures. Native
electrophoresis shows that the murine mTFOwt, which
has four AGGG repeats, forms a high molecular weight
species in potassium: probably a quadruplex concatena-
mer of several strands which, according to CD, has a Tm
of 718C (Supplementary Data, S1). When however the
TFO is modiﬁed with two or three bulge TINA insertions,
it has a much lower tendency to aggregate, most likely
because the guanine runs are disrupted by the pyrene
intercalator (there should be 26 intercalating units per
concatenamer of eight strands). The human hTFOwt
having a less regular guanine distribution forms a
structure that, according to electrophoresis, could be a
dimeric parallel quadruplex with a Tm of 508C (38). This
structure is not formed by the TINA analogues 1453, 1454
and 1455 because the bulge insertions in these oligonu-
cleotides strongly destabilize the quadruplex. It is remark-
able that 1455, where the bulge insertions are placed
outside or adjacent to the guanine runs, shows some
aggregation. This suggests that when the pyrenyl inser-
tions are put inside the guanine runs, they destabilize the
G-quartets and reduce or abrogate self-aggregation, but
when they are located adjacent to or outside the guanine
Nucleic Acids Research, 2008, Vol. 36, No. 10 3505runs, the formation of the G-quartet structure is only
partially disturbed.
As regards the binding speciﬁcity of the designed TINA
TFOs, the data presented here show that, though the
TINA insertion is a non-sequence speciﬁc modiﬁcation,
the conjugates maintain the binding speciﬁcity typical of
TFOs. The target with four G-to-A mutations is not
recognized by the designed TINA–TFOs, and control
TINA TFOs 1456 and 1457 do not bind to the pur/pyr
sequence either. Moreover, we found that pyrimidine
TINA TFOs containing two or three TINA insertions, just
as the purine TFOs, did not bind to the murine and
human KRAS targets at pH 7.4.
Molecular dynamic calculations show that the pyrenyl
moieties intercalate into the double helix portion of the
triplex promoting stacking interactions that further
stabilize the structure. The conjugates 1453 and 1454
have bulge insertions between G3-G4 and G11-G12, but
1453 has one more insertion between A16-A17. EMSA
shows that 1454 (G=–9.8kcal/mol) with only two
insertions forms a more stable triplex than 1453 (G=
 8.8kcal/mol), probably because the accommodation in
the latter of three bulged 1-methylethynylpyrenes may
slightly distort the structure of the triplex, thus destabiliz-
ing it. This comparison does not hold for the murine
sequence, because the bulge insertions are located in
diﬀerent places in the various conjugates. A systematic
study on the eﬀect of the number and position of the bulge
insertions on triplex formation will be necessary to gain
more insight into this issue. We also synthesized for the
murine KRAS pur/pyr target pyrimidine TINA–TFOs,
which bind to DNA in the parallel fashion. Although
TINA monomers stabilize parallel triplexes (27), the high
cytosine content of the pyrimidine TINA–TFOs only
allows triplex formation at pH 6, but not at pH 7, even
though the TFOs contained 5-methylcytosine (53). This
suggests that pur/pyr sites with a high C+G content
(>50%) can be eﬃciently targeted only by purine TINA–
TFOs.
The antigene activity of the TINA–TFOs was evaluated
by co-transfecting NIH 3T3 cells with plasmid pKRS-413,
which contains CAT driven by the KRAS promoter, and
TINA–TFOs. Interestingly, murine TFOs 1037, 1451 and
1452 were found to inhibit roughly 50% CAT expression,
compared to control 1456 and 1457. As this inhibition
could be attributed to aptameric eﬀects promoted by the
TFOs against the proteins binding to the pur/pyr element,
we mutated the pur/pyr sequence in pKRS-413 (by
introducing four G-to-A mutations). The results obtained
showed that the designed TINA–TFOs did not aﬀect the
CAT expression by the mutant plasmid, whereas CAT was
signiﬁcantly inhibited by the 2218, a TINA–TFO that
binds to the mutant pur/pyr target. We have seen that the
CAT inhibition promoted by the TINA–TFOs nicely
correlates with their capacity to block protein binding to
the KRAS pur/pyr site. This blocking was observed either
when we added TFO and extract simultaneously to the
target, and also when we allowed the triplex to be formed
before the protein extract was added. Considering that the
mean residence time on DNA of transcription factors
should be in the order of few tens of seconds (54),
the TFOs should not need to compete with existing DNA–
protein complexes to inhibit transcription.
In conclusion, the present study opens new perspectives
in the sequence-selective targeting of duplex DNA by
using the triplex oligonucleotide technology.
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